Correction: LRG1 as a novel therapeutic target in eye disease.

Eye (Lond)

Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.

Published: May 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170153PMC
http://dx.doi.org/10.1038/s41433-022-01988-6DOI Listing

Publication Analysis

Top Keywords

correction lrg1
4
lrg1 novel
4
novel therapeutic
4
therapeutic target
4
target eye
4
eye disease
4
correction
1
novel
1
therapeutic
1
target
1

Similar Publications

Article Synopsis
  • - Psychosis risk prediction in psychiatry is challenging, and a study aimed to evaluate whether a specific proteomic model could accurately predict the transition to psychosis in individuals at clinical high risk, using plasma samples from three cohorts totaling 754 participants.
  • - The study found that only 20.4% of participants developed psychosis over about 4.4 years, and the prediction model had poor accuracy (C-statistic: 0.51), suggesting that the proteomic factors didn't reliably predict outcomes.
  • - Some proteins, like Complement C8B and LRG1, showed weak associations with psychosis transition but did not reach significant levels when correcting for multiple comparisons, indicating that previous claims based on small sample sizes should
View Article and Find Full Text PDF

Reversal of emphysema by restoration of pulmonary endothelial cells.

J Exp Med

August 2021

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY.

Chronic obstructive pulmonary disease (COPD) is marked by airway inflammation and airspace enlargement (emphysema) leading to airflow obstruction and eventual respiratory failure. Microvasculature dysfunction is associated with COPD/emphysema. However, it is not known if abnormal endothelium drives COPD/emphysema pathology and/or if correcting endothelial dysfunction has therapeutic potential.

View Article and Find Full Text PDF

Correcting an instance of synthetic lethality with a pro-survival sequence.

Biochim Biophys Acta Mol Cell Res

September 2020

Department of Chemistry and Chemical Engineering, Royal Military College, Kingston, Ontario, Canada. Electronic address:

A human cDNA encoding the LIM domain containing 194 amino acid cysteine and glycine rich protein 3 (CSRP3) was identified as a BAX suppressor in yeast and a pro-survival sequence that abrogated copper mediated regulated cell death (RCD). Yeast lacks a CSRP3 orthologue but it has four LIM sequences, namely RGA1, RGA2, LRG1 and PXL1. These are known regulators of stress responses yet their roles in RCD remain unknown.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!